Lack of TERT promoter mutations in melanomas with extensive regression - 16/02/16
Doi : 10.1016/j.jaad.2015.10.003
Blanca de Unamuno Bustos, MD a, Rosa Murria Estal, MSc c, Gema Pérez Simó, BSc c, Vicente Oliver Martínez, MD, PhD d, Margarita Llavador Ros, MD b, Sarai Palanca Suela, PhD c, ⁎∗ 
, Rafael Botella Estrada, MD, PhD a, ∗
, Rafael Botella Estrada, MD, PhD a, ∗ a Department of Dermatology, University Hospital La Fe, Spain
b Department of Pathology, University Hospital La Fe, Spain
c Molecular Biology Laboratory, Service of Clinical Analysis, University Hospital La Fe, Spain
d Department of Dermatology, University General Hospital of Valencia, Spain
∗Correspondence to: Sarai Palanca Suela, PhD, Molecular Biology Laboratory, Service of Clinical Analysis, University Hospital La Fe, Avda de Fernando Abril Martorell, n.106, 46026 Valencia (Spain)Molecular Biology LaboratoryService of Clinical AnalysisUniversity Hospital La FeAvda de Fernando Abril Martorell, n.10646026 ValenciaSpain
| Funding sources: This study was supported in part by the Health Research Institute La Fe for having granted the project IISLaFe 2014/0370 and the Carlos III Health Institute for having granted the project PIE13/00046. |
|
| Conflicts of interest: None declared. |
© 2015
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 74 - N° 3
P. 570-572 - mars 2016 Retour au numéro
Article précédent
- Experience with topical timolol maleate for the treatment of ulcerated infantile hemangiomas (IH)
- Markus D. Boos, Leslie Castelo-Soccio
- High specificity and sensitivity of NRAS Q61R immunohistochemistry (IHC) in melanomas
- Pierre-Alexandre Just, Christelle Pouliquen, Anne Audebourg, Sara Laurent-Roussel, Agnès Carlotti, Nicolas Dupin, Marie-Cécile Vacher-Lavenu, Michel Vidaud, Benoît Terris, Eric Pasmant
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?